Incyte Corporation (INCY)
Incyte Announces Positive CHMP Opinion for Minjuvi®(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
Incyte Announces Positive CHMP Opinion for Minjuvi®(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
There are no comments here yet...